Mohammad Hamouz

Dr. Mohammad Hamouz

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MHMohammad Hamouz
Mohammad Hamouz
RHRaneem Yaseen Hammouz
Raneem Yaseen Hammouz
Muhammad BajwaMuhammad Bajwa
Muhammad Bajwa
AAAbdelrahman Waleed Alsayed
Abdelrahman Waleed Alsayed
Magdalena Julita Krystkiewicz-OrzechowskaMagdalena Julita Krystkiewicz-Orzechowska
Magdalena Julita Krystkiewicz-Orzechowska
ABAndrzej Bednarek
Andrzej Bednarek
There is currently a dearth of information regarding lung cancer in never smokers (LCINS). Additionally, there is a difference in somatic mutations, tumour mutational burden, and chromosomal aberrations between smokers and never smokers (NS), insinuating a different disease entity in LCINS. A better understanding of actionable driver alterations prevalent in LCINS and the genomic landscape will contribute to identifying new molecular targets of relevance for NS that will drastically improve outcomes. Differences in treatment outcomes between NS and smokers, as well as sexes, with NSCLC suggest unique tumour characteristics. Epidermal growth factor receptor (EGFR) tyrosine kinase mutations and echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) gene rearrangements are more common in NS and have been associated with chemotherapy resistance. Moreover, NS are less likely to benefit from immune mediators including PD-L1. Unravelling the genomic and epigenomic underpinnings of LCINS will aid in the development of not only novel targeted therapies but also more refined approaches. This review encompasses driver genes and pathways involved in the pathogenesis of LCINS and a deeper exploration of the genomic landscape and tumour microenvironment. We highlight the dire need to define the genetic and environmental aspects entailing the development of lung cancer in NS.

2 April 2026 in Cellular and Molecular Bioengineering
Verified
Journal Article
Open access
PDF file
MHMohammad Hamouz
Mohammad Hamouz
RHRaneem Yaseen Hammouz
Raneem Yaseen Hammouz
CCChristine Caruana
Christine Caruana
DMDenise Micallef
Denise Micallef
ABAndrzej Bednarek
Andrzej Bednarek
PDPhilip Dingli
Philip Dingli
Cardiac fibrosis represents a complex pathological process driven by persistent fibroblast activation, dysregulated cardiomyocyte-ECM crosstalk, and maladaptive mechanotransduction, ultimately resulting in myocardial stiffening and progressive heart failure. This review integrates insights from single-cell and spatial transcriptomics, biomechanical studies, and epigenetic profiling to illuminate the cellular heterogeneity and molecular circuits underlying fibrotic remodelling. We highlight emerging therapies including CRISPR-based gene editing, FAP-targeted CAR-T immunotherapy, nanomedicine for selective RNA delivery, and patient-derived cardiac organoids; that collectively position fibrosis as a reversible and actionable target. Finally, we discuss precision medicine strategies leveraging genomics, circulating biomarkers, artificial intelligence, and environmental risk assessment to deliver personalized anti-fibrotic interventions. By uniting mechanobiology, molecular engineering, and clinical innovation, this review charts a translational roadmap toward durable reversal of cardiac fibrosis. Graphical Abstract

19 April 2026 in Cellular and Molecular Bioengineering
Verified
Journal Article
Closed access
MHMohammad Hamouz
Mohammad Hamouz
RHRaneem Yaseen Hammouz
Raneem Yaseen Hammouz
CCChristine Caruana
Christine Caruana
DMDenise Micallef
Denise Micallef
ABAndrzej Bednarek
Andrzej Bednarek
PDPhilip Dingli
Philip Dingli